Sun Pharmaceutical Industries Share Price

₹ 1,829.00

+₹55.60 (3.14%)
1D
Last updated 05 Nov, 2026, 15:56 IST
NSE: SUNPHARMA
|
Pharmaceuticals

Sun Pharmaceutical Industries Share Price Today

As of 6 Nov 2026, Sun Pharmaceutical Industries share price is ₹1,829.00. The stock opened at ₹1,774.00, compared to its previous close of ₹1,773.40. During today's trading session, Sun Pharmaceutical Industries share price moved in the range of ₹1,762.40 to ₹1,839.70, with an average price of ₹1,801.05 for the day. Looking at its last 52-week, the stock has touched a low of ₹1,583.70 and a high of ₹2,046.90. On the performance front, Sun Pharmaceutical Industries share price has increased by 0.45% over the last six months and is up 8.22% on a year-on-year basis.

Share price over the last 1 day rose from 1781.60 to 1829.00, ranging between 1781.60 and 1838.80.
₹1,762.40
3.14% up today
₹1,839.70
1D LOW
1D HIGH

Sun Pharmaceutical Industries Stock Insights

Latest Earning
Op Profit TrendUp by 9.94% YoY
Latest Earning
Net Profit TrendUp by 5.32% YoY
Latest Earning
Revenue TrendUp by 4.32% QoQ
Stock Performance
OutperformingBeat Nifty by 11.26 % in last 1 year
Shareholding Pattern
PromoterPromoter decreased stake by 3.30%
Shareholding Pattern
DIIDII decreased stake by 0.82%
Shareholding Pattern
FIIFII decreased stake by 1.20%
Technical Indicators
Volume SpikeVolume is 136.0% above 20-day average on 1 Day interval.
Sun Pharmaceutical Industries stock performance
Open₹1,774.00
High₹1,839.70
Low₹1,762.40
Prev. close₹1,773.40
Sun Pharmaceutical Industries trading activity
Volume39,23,834
Average traded price₹1,820.50
Last traded time03:56:50 05 Nov
Last traded quantity35
Circuit
L
H
₹1,775.50
₹1,885.30
52-week
L
H
₹1,583.70
₹2,046.90
Mkt Cap Cr
4,26,121.89
P/E
38.79
P/B
4.77
ROA
9.61%
ROE
13.79%
ROCE
18.65%
Quick Ratio
2.31
EV/EBITDA
22.17

Based on fundamentals, this stock's

Performance: 2 out of 5, Poor
Performance
Poor
Sun Pharma.Inds. has underperformed the market
Valuation: 1 out of 5, Overvalued
Valuation
Overvalued
Sun Pharma.Inds. appears overvalued compared to its peers
Earnings: 4 out of 5, Good
Earnings
Good
Sun Pharma.Inds. revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROAROEROCEQuick RatioEV/EBITDA
Divis Laboratories2,66,424.2791.0915.914.6%15.32%19.56%3.560.7
Torrent Pharmaceuticals1,76,300.5085.729.794.7%11.42%11.37%0.7533.85
Laurus Labs1,24,601.4093.5220.5611.58%22.11%20.91%0.6852.92
Zydus Lifesciences1,18,702.9627.594.278.08%18.59%17.35%0.9116.36
Dr. Reddy's Laboratories1,14,518.1441.52.954.79%7.21%8.58%1.3519.27
Cipla1,12,471.7539.633.26.6%8.18%10.8%2.521.31
Mankind Pharma1,04,630.5246.235.957.82%12.76%14.68%0.7424.84
Aurobindo Pharma97,756.7126.382.586.34%9.25%11.76%1.1512.48
Lupin92,144.5417.653.8313.91%23.76%24.88%1.429.85
Glenmark Pharma70,608.3839.286.729.03%28.08%32.7%1.2320.09

Auto-generated based on historical fundamentals; not a recommendation to buy/sell.

Sun Pharmaceutical Industries Company Background

ISIN
INE044A01036
Sector Market Cap
₹ 426,121.89 Cr

Sun Pharmaceutical Industries Ltd is the world’s fourth-largest specialty generic pharmaceutical company. With a network of over 40 manufacturing facilities, the company distributes medicines to more than over 100 countries worldwide. The company has a global employee base of over 41,000.

The company’s recent acquisition of Concert Pharmaceuticals Inc in the United States has granted it access to the late-stage asset deuruxolitinib, which has completed Phase-3 studies for treating alopecia areata. Founded in 1983, Sun Pharma has a market capitalisation of ₹2,98,705 crore as of December 19, 2023. Sun Pharma share price has gained 114% in the last 3 years.

Business portfolio

The company manufactures and markets a wide range of pharmaceutical formulations, which include generics, branded generics, over-the-counter, antiretrovirals, intermediates and active pharmaceutical ingredients. In specialty medications, Sun Pharma has a portfolio of patent-protected drugs. With focus on dermatology, ophthalmology and oncology, the company aims to improve patient outcomes by addressing unmet medical needs and enhancing convenience through diverse dosage forms.

Sun Pharma provides high-quality generic and branded medicines to patients and healthcare professionals in over 100 countries. These medicines are available in tablets, capsules, injectables, inhalers, ointments, creams and liquids.

The therapeutic segments covered by the company’s portfolio includes psychiatry, anti-infectives, neurology, cardiology, orthopaedics, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Sun Pharma consistently ranks among the leading companies in these therapy areas. Presently, it’s one of the top companies in the United States, having introduced a number of speciality items.

When it comes to over-the-counter medications, Sun Pharma’s range is diverse. Its flagship OTC brands such as Faringosept (sore throat), Revital (vitamins) and Volini (topical analgesics) are available globally.

With regards to active pharmaceutical ingredients (APIs), Sun Pharma began producing them in 1995. The company manufactures more than 300 APIs that are sold in over 60 countries. These are manufactured in 14 sites spread across India, Hungary, the United States, Israel and Australia.

Sun Pharma provides a selection of antiretroviral (ARV) drugs that have been prequalified by the WHO. The company works with groups like the Clinton Health Access Initiative (CHAI) to lower the cost of triple medication combinations and provides ARVs to various National AIDS treatment programmes in Africa.

Bioequivalent ARV medications and APIs are produced at WHO-prequalified facilities in India, a PIC/S-approved facility in South Africa and a plant in Russia, all of which are part of Sun Pharma’s portfolio.

Sun Pharmaceutical Industries Financial Highlights

  • Revenue: Sun Pharmaceutical Industries reported revenue of ₹60,433.76 crore in FY26 vs ₹54,543.48 crore in FY25. It showed an increase of 10.80% on a yearly basis.
  • Operating Profit: Sun Pharmaceutical Industries reported an operating profit of ₹15,118.88 crore in FY26 vs ₹13,752.13 crore in FY25. It showed an increase of 9.94% on a year-on-year basis.
  • Net Profit: Sun Pharmaceutical Industries reported a net profit of ₹11,564.52 crore in FY26 vs ₹10,980.10 crore in FY25. It showed an increase of 5.32% on a yearly basis.

Sun Pharmaceutical Industries Quarterly Result Highlights

  • Sun Pharmaceutical Industries reported revenue of ₹16,716.03 crore in Sep 2026, compared with ₹16,023.50 crore in Jun 2026, representing an increase of 4.32% on a quarter-on-quarter (QoQ) basis.
  • Sun Pharmaceutical Industries reported an operating profit of ₹3,159.37 crore in Sep 2026, compared with ₹4,098.81 crore in Jun 2026, representing a decrease of 22.92% on a quarter-on-quarter (QoQ) basis.
  • Sun Pharmaceutical Industries reported a profit of ₹2,001.58 crore in Sep 2026, compared with ₹2,910.80 crore in Jun 2026, reflecting a decrease of 31.24% on a QoQ basis.
  • The earnings per share (EPS) of Sun Pharmaceutical Industries stood at ₹47.80 during Sep 2026.

Data Source: BSE, Company announcements

Securities shown are illustrative, not recommendations. Past performance does not guarantee future results.

Promoters
52.68%
FII
14.36%
Other DII
9.26%
Retail and other
10.70%
Mutual funds
13.01%
Foreign Institutional Investor (FII)
FII shareholding by period
Dec 202516.12%
Mar 202615.93%
Jun 202614.53%
Sep 202614.36%

Sun Pharmaceutical Industries Investment Returns

1 day
+3.14%
1 week
+3.86%
1 month
+2.77%
1 year
+8.22%
3 years
+60.28%
5 years
+129.93%

Sun Pharmaceutical Industries Share Price History

Sun Pharmaceutical Industries share price history by day, showing open and close prices and the percentage change
Day
Open / Close
Change %
05 Nov 26
₹1,774.00 / ₹1,829.00
+3.14%
04 Nov 26
₹1,769.90 / ₹1,773.40
+0.20%
03 Nov 26
₹1,766.10 / ₹1,769.90
-0.01%
02 Nov 26
₹1,770.00 / ₹1,770.00
-0.43%
Show more

Sun Pharmaceutical Industries Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹58,462.04₹52,578.44₹48,496.85₹43,885.68
Other Income₹3,211.90₹2,150.57₹1,390.32₹634.52
Total Revenue₹61,673.94₹54,729.01₹49,887.17₹44,520.20
Total Expenses₹45,247.58₹40,299.03₹38,304.96₹34,940.32
Profit Before Tax₹15,118.88₹13,752.13₹11,087.89₹9,408.43
Tax₹3,554.36₹2,772.03₹1,439.45₹847.59
Profit After Tax₹11,564.52₹10,980.10₹9,648.44₹8,560.84
EPS - Basic₹47.80₹45.60₹39.90₹35.30
EPS - Diluted₹47.80₹45.60₹39.90₹35.30

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹15,118.88₹13,752.13₹11,087.89₹9,408.43
Income before WC changes₹16,000.91₹14,872.49₹12,642.29₹12,130.99
Change in Assets-₹2,270.62-₹1,845.34₹567.80-₹2,371.18
Change in Liabilities₹1,002.83₹1,521.78₹494.33-₹3,290.64
Change in WC-₹1,267.79-₹323.56₹1,062.13-₹5,661.82
Cash flow from Operations₹12,419.18₹14,072.09₹12,134.98₹4,959.33
Cash flow from Investing-₹11,344.05-₹5,306.16-₹690.20-₹7,943.68
Cash flow from Financing-₹2,512.55-₹7,905.82-₹6,710.16₹2,376.07
Total Cash Flow-₹1,437.42₹860.11₹4,734.62-₹608.28
Cash (Start of the year)₹10,268.77₹9,285.65₹4,623.73₹4,508.25
Cash (End of the year)₹9,770.51₹10,268.77₹9,285.65₹4,623.73

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹44,924.93₹39,506.52₹42,066.54₹40,881.65
Current Assets₹63,860.29₹52,594.06₹43,433.11₹39,861.94
Total Assets₹108,785.22₹92,100.58₹85,499.65₹80,743.59
Current Liabilities₹22,622.04₹18,194.21₹16,983.77₹19,906.38
Net Current Asset₹41,238.25₹34,399.85₹26,449.34₹19,955.56
Non-Current Liabilities₹2,283.44₹1,420.42₹1,389.94₹1,521.74
Equity Capital₹83,879.74₹72,485.95₹67,125.94₹59,315.47
Total Equity & Liabilities₹108,785.22₹92,100.58₹85,499.65₹80,743.59

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenue₹20,754.64₹22,977.40₹20,275.17₹20,812.14
Other Income₹1,776.43₹634.33₹553.48₹329.29
Total Revenue₹22,531.07₹23,611.73₹20,828.65₹21,141.43
Total Expenses₹18,190.61₹18,635.52₹17,159.98₹16,462.59
Profit Before Tax₹3,794.12₹4,976.21₹3,449.65₹1,741.05
Tax₹1,170.70₹748.13₹591.47₹50.33
Profit After Tax₹2,623.42₹4,228.08₹2,858.18₹1,690.72
EPS - Basic₹10.90₹17.60₹11.90₹7.00
EPS - Diluted₹10.90₹17.60₹11.90₹7.00

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before tax₹3,794.12₹4,976.21₹3,449.65₹1,741.05
Income before WC changes₹5,258.30₹6,759.57₹5,218.56₹6,564.45
Change in Assets₹1,307.69-₹2,967.65-₹1,188.02-₹3,599.99
Change in Liabilities₹335.55₹593.78-₹3,981.09-₹2,025.39
Change in WC₹1,643.24-₹2,373.87-₹5,169.11-₹5,625.38
Cash flow from Operations₹6,500.87₹4,251.97-₹292.42₹507.08
Cash flow from Investing-₹1,380.95-₹258.17-₹262.91-₹705.17
Cash flow from Financing-₹5,230.18-₹3,836.13₹473.95₹169.31
Total Cash Flow-₹110.26₹157.67-₹81.38-₹28.78
Cash (Start of the year)₹492.57₹327.37₹410.28₹419.53
Cash (End of the year)₹417.84₹492.57₹326.46₹410.28

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assets₹26,380.82₹25,097.77₹26,152.25₹24,543.74
Current Assets₹16,678.72₹18,780.70₹14,912.54₹16,443.75
Total Assets₹43,059.54₹43,878.47₹41,064.79₹40,987.49
Current Liabilities₹6,503.24₹18,202.38₹4,444.51₹8,365.44
Net Current Asset₹10,175.48₹578.32₹10,468.03₹8,078.31
Non-Current Liabilities₹14,185.54₹1,775.80₹12,925.88₹8,873.69
Equity Capital₹22,370.76₹23,900.29₹23,694.40₹23,748.36
Total Equity & Liabilities₹43,059.54₹43,878.47₹41,064.79₹40,987.49
* All values are in INR Crore
Sun Pharmaceutical Industries market depth
Bid quantityBid priceAsk priceAsk quantity
38182900
0000
0000
0000
0000
Total bid quantity38
Total ask quantity0
Sun Pharmaceutical Industries technical summary
Bearish indicators2
Neutral indicators5
Bullish indicators1
OverallSlightly Bearish
by SEBI experts

Expert Pick

EXPPICK
Stop-loss
Stop-loss is locked. Sign in to view.
Entry price
Entry price is locked. Sign in to view.
Target
Target is locked. Sign in to view.
Indicator
Value
Verdict
RSI (14)
46.84
Neutral
ATR (14)
39.47
Neutral
STOCH(9,6)
38.65
Neutral
STOCH RSI (14)
93.36
Bearish
ADX(9)
40.1
Bearish
UO(9)
47.14
Neutral
ROC(12)
0.83
Bullish
WillR(14)
-60.04
Neutral
Period
Simple value
Exponential vaue
5D
1770.4
1768.89
10D
1760.67
1765.47
20D
1759.78
1772.93
50D
1826.95
1811.03
100D
1869.77
1831
Volume trend — traded volume by day
5 Nov39L
4 Nov49L
3 Nov26L
2 Nov34L
30 Oct51L
Average40L

Technical indicators used here are for indicative purposes only. Kindly do not treat it as an investment or trading advice

Compare against other stocks

Sun Pharmaceutical Industries
Pharmaceuticals
Add Stock
Add Another

Mutual Funds Invested in Sun Pharmaceutical Industries

Fund name
AUM
ICICI Prudential Nifty Pharma Index Fund
21.81%
DSP Nifty Healthcare Index Fund
18.32%
Bandhan BSE Healthcare Index Fund
13.49%

Sun Pharmaceutical Industries Returns Calculator

Ex-date: 07 Jul 2026
Ex-date: 05 Feb 2026

Sun Pharmaceutical Industries Latest News

6 days ago
Sun Pharmaceutical Q2 FY27 result: Net profit declines 36% YoY; US formulation sales falls to $455 million
2 weeks ago
Max Healthcare, Apollo Hospitals, Sun Pharma, Dr Reddy’s: Stocks trade lower as NPPA caps cancer drug margins
3 weeks ago
Dr Reddy’s, Torrent Pharma, Zydus Life: Pharma stocks to post resilient growth in Q2 earnings despite pricing headwinds
3 weeks ago
Sun Pharma, Dr Reddy’s, Max Healthcare: Pharma, hospital stocks rise up to 6% amid anti-cancer drug margin cap on MRP
1 month ago
SENSEX loses 330 pts, NIFTY50 snaps 4-day winning streak amid mixed global cues
1 month ago
Sun Pharma, Mankind Pharma, Wockhardt, other pharma stocks surge up to 6%, Nifty Pharma up 1.5%; key things to know
1 month ago
Sun Pharma to Zydus: Healthcare stocks outperform broader market despite price pressure; can they sustain growth?
2 months ago
Sun Pharma, Laurus Labs, Mankind Pharma, others drag Nifty Pharma down 1.6%; here’s what investors should know
2 months ago
Stocks to watch, Sept 1: Auto stocks, ITC, Happiest Minds, PVR Inox, Milky Mist, Sun Pharma, TBZ, UltraTech Cement
2 months ago
Top gainers and losers, Aug 31: Adani Ent falls 10%, Adani Ports declines 7%, Sun Pharma rises 3%; check list
Showing news item 1 of 10

Top Gainers

UNOMINDA Share Price
₹1335.00
+138.1 (+11.54%)
ASHOKLEY Share Price
₹170.21
+16.18 (+10.5%)
DEVYANI Share Price
₹129.21
+10.53 (+8.87%)
SOBHA Share Price
₹1291.90
+103.9 (+8.75%)
FIVESTAR Share Price
₹429.85
+32.7 (+8.23%)
See more

Top Losers

PIIND Share Price
₹1770.00
-417 (-19.07%)
CUMMINSIND Share Price
₹4058.90
-666.8 (-14.11%)
APTUS Share Price
₹179.93
-26.35 (-12.77%)
GMMPFAUDLR Share Price
₹1194.20
-126 (-9.54%)
CHENNPETRO Share Price
₹1418.50
-148.4 (-9.47%)
See more

Sun Pharmaceutical Industries Share Price FAQs

Please be aware that Sun Pharmaceutical Industries stock prices are subject to continuous fluctuations due to various factors.